Anthropic's IPO, Platner's Campaign Controversies, and Blue Origin's Setback

What It Covers

Kara Swisher and Scott Galloway cover Anthropic's confidential IPO filing after surpassing OpenAI's $730B valuation to reach $965B in five years, Maine Senate candidate Graham Plattner's sexting controversy, Blue Origin's New Glenn rocket explosion on the launch pad, and the podcasting acquisition market.

Key Questions Answered

• •Anthropic's valuation speed: Anthropic reached a $965B valuation in five years — half the time OpenAI needed to hit $730B. The key strategic move was targeting enterprise customers rather than consumers. Google took 20 years to reach $1T. This speed represents what Galloway calls "financial teleportation," not normal capital formation.
• •AI investment risk concentration: 93% of US GDP growth currently derives from AI capital expenditure, creating dangerous market concentration. An MIT study shows 95% of CFOs report no measurable ROI on AI investments. When one major company announces spending cuts, the resulting market correction could trigger a recession equivalent to losing Germany's entire GDP.
• •Podcast acquisition dynamics: Podcast ad CPMs average $45 versus $13 for CNN, making the medium highly attractive to acquirers. RSS feed subscribers create durable moats that new entrants cannot replicate quickly. Top-ranked podcasts are almost always long-established shows, meaning scale commands 10x revenue multiples — a show with 10M monthly downloads is worth 4x one with 5M.
• •Crisis communications failure pattern: The Plattner campaign kept a damaging story alive by denying accurate reporting and attacking media outlets rather than owning the mistakes. The correct response framework: acknowledge specific failures, contextualize them within a broader record of service, and redirect to policy. Denial of corroborated facts extends news cycles indefinitely.
• •GLP-1 drugs vs. AI as investment thesis: Eli Lilly, headquartered in Indianapolis, became the first pharmaceutical company to breach a $1T market cap by betting early on GLP-1 drugs. Monthly costs dropped from $1,000 to $250–$500 within 12 months, demonstrating strong price elasticity. Galloway argues going long GLP-1 and short AI is the stronger decade-long investment position.